Rinvoq is a Oral Tablet, Extended Release in the Human Prescription Drug category. It is labeled and distributed by Abbvie Inc.. The primary component is Upadacitinib.
Product ID | 0074-2306_0c1f0eb7-336d-4a9a-a348-e7c5212e3f73 |
NDC | 0074-2306 |
Product Type | Human Prescription Drug |
Proprietary Name | Rinvoq |
Generic Name | Upadacitinib |
Dosage Form | Tablet, Extended Release |
Route of Administration | ORAL |
Marketing Start Date | 2019-08-16 |
Marketing Category | NDA / NDA |
Application Number | NDA211675 |
Labeler Name | AbbVie Inc. |
Substance Name | UPADACITINIB |
Active Ingredient Strength | 15 mg/1 |
NDC Exclude Flag | N |
Listing Certified Through | 2022-12-31 |
Marketing Start Date | 2019-08-16 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | NDA |
Application Number | NDA211675 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | EA |
Marketing Start Date | 2019-08-16 |
Marketing Category | NDA |
Application Number | NDA211675 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | EA |
Marketing Start Date | 2019-08-16 |
Ingredient | Strength |
---|---|
UPADACITINIB | 15 mg/1 |
SPL SET ID: | 2966aec7-2ef0-923c-d8ff-fe1a957bf095 |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI |
NDC | Brand Name | Generic Name |
---|---|---|
0074-1043 | Rinvoq | Upadacitinib |
0074-2306 | Rinvoq | Upadacitinib |
0074-2310 | Rinvoq | Upadacitinib |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
RINVOQ 87320921 5908540 Live/Registered |
AbbVie Biotechnology Ltd. 2017-02-01 |